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Abstract 
 
Patients at the Intensive Care Unit (ICU) typically present with decreased plasma triiodothyronine 
(T3), low thyroxine (T4), and normal range or slightly decreased thyroid stimulating hormone (TSH) . 
This ensemble of changes is collectively known as the non-thyroidal illness syndrome (NTIS). The 
extent of the NTIS correlates with prognosis, but there is no proof for causality of this association.  
Initially, NTIS reflects the acute phase response to systemic illness as well as macronutrient 
restriction, and may be beneficial. The pathogenesis of NTIS in prolonged critical illness is more 
complex and includes suppressed hypothalamic thyrotropin releasing hormone (TRH) production, 
explaining persistently reduced TSH secretion in spite of low plasma TH. In some cases it is difficult to 
distinguish between NTIS and severe hypothyroidism which is a rare primary cause for ICU admission. 
Infusing hypothalamic releasing factors can reactivate the thyroid axis in patients with NTIS, inducing 
an anabolic response. If this approach carries clinical benefit in terms of outcome is currently 
unknown. In this review, we will discuss diagnostic aspects, pathogenesis and implications of NTIS as 
well as its distinction from severe primary thyroid disorders in ICU patients.   
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Introduction 
 
The hypothalamus–pituitary–thyroid (HPT) axis is controlled by a classical endocrine feedback loop. 
Thyrotropin-releasing hormone (TRH) is released at the level of the hypothalamus which stimulates 
the anterior pituitary to secrete thyroid stimulating hormone (TSH). In turn, TSH drives the thyroid 
gland to release thyroid hormones (TH). The prohormone thyroxine (T4) is converted in peripheral 
tissues to the active hormone triiodothyronine (T3). Hypothalamic TRH neurons were identified as 
determinants of TH setpoint regulation over three decades ago, and this was followed by the 
demonstration of a key role played by thyroid hormone receptor (TR) β in TH negative feedback both 
at the level of the hypothalamus and anterior pituitary. Thus, the HPT axis was assumed to have a 
fixed setpoint, aiming at individually determined TH serum concentrations. 1 However, more recent 
studies showed that TH serum concentrations can be variable and adaptive in response to 
environmental factors, including the nutrient availability and inflammatory stimuli 2.  
Marked changes in TH plasma concentrations have been observed in a variety of diseases, 
characterized by clearly decreased plasma T3, low plasma T4, and increased plasma reverse T3 (rT3) 
concentrations. In spite of the low T3 and T4, TSH is typically within the normal range or slightly 
decreased.  This ensemble of changes in thyroid function tests is collectively known as the “non-
thyroidal illness syndrome” (NTIS). 3 The presentation, pathogenesis, metabolic consequences, and 
clinical management of thyroid dysfunction in critically ill patients will be the focus of the current 
review. The distinction between NTIS in ICU patients and primary thyroid disorders in ICU patients 
can sometimes be difficult, and will be briefly touched upon as well.  
 
 
Description of Nonthyroidal illness  
 
Both in humans and rodents, illness decreases TH serum concentrations without a concomitant rise 
in serum TSH. This reflects a deviation from “normal” negative feedback regulation in the HPT axis. 
Should a similar drop in serum T3 and T4 occur in the context of primary hypothyroidism, serum TSH 
would be markedly elevated and the patient would be in need of treatment with TH replacement 
therapy. The combination of low serum T3 and serum TSH within the reference range in the context 
of illness is called NTIS.3 4 Several alternative names have been used to refer to NTIS, including the 
“sick euthyroid syndrome” and the “low T3 syndrome” 5, the latter term pointing to low plasma T3 as 
the most consistent and striking alteration; in this review we will use the term NTIS.  
Very rapidly after the onset of acute stress, such as myocardial infarction or surgery, serum T3 
decreases. In patients undergoing abdominal surgery, a fall in serum T3 was observed already after 2 
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hours. 6 NTIS has been reported in patients with acute and chronic illnesses, including infectious 
diseases, cardiovascular and gastrointestinal diseases, cancer, burns and trauma. 4 Serum T3 
decreases further as the severity of the disease progresses. This is reflected in the reported 
correlations between the size of a myocardial infarction, the increase in serum creatinine in renal 
insufficiency and burn severity on the one hand, and the fall in serum T3 on the other hand. 4 
Therefore, the magnitude of the drop in plasma TH levels generally reflect the severity of the 
condition and as a consequence, could have prognostic significance. In one study performed in ICU 
patients, the sensitivity and specificity in predicting mortality were 75% and 80%, respectively, for 
serum T4 <40 nmol/L .7 For combined low serum T4 and high serum cortisol these number were even 
higher, i.e., 100% and 81%. Likewise, low T3 was shown to be a strong predictor of mortality in 
patients with heart disease. 8 
NTIS is present in most, if not all, in critically ill patients, which can be defined as any life-threatening 
condition that requires support of vital organ function without which death would be imminent. 9 
Thus, critically ill patients that require prolonged treatment in the intensive care unit (ICU) typically 
exhibit decreased plasma T3 and T4 concentrations. An absent TSH response in this context points to 
profoundly altered HPT axis feedback regulation. 10 Although the normal TSH level in the presence of 
the low plasma T3 concentrations has been interpreted as indicating a “euthyroid” status, this 
assumption has not been substantiated by experimental data. The typical changes in plasma TH 
parameters that can be easily assessed in the clinical setting are the result of alterations in the 
central regulation of the thyroid axis, including decreased TSH pulsatility. 10 Moreover, several 
alterations occur in the peripheral components of the thyroid axis that vary according to the tissue as 
well as the severity of illness. 11 The peripheral changes include, but are not limited to, altered 
concentrations of the TH binding proteins and TH transporters, changes in the expression and activity 
of the TH deiodinases and alterations in TH receptor expression. 3 Changes in thyroid parameters that 
are similar, but not identical to those observed during NTIS, occur in response to fasting in healthy 
subjects 12. The NTIS in response to fasting in healthy subjects is regarded adaptive and beneficial by 
reducing energy expenditure to limit catabolism via decreased TH action. 
At present it is unknown if the NTIS occurring in response to critical illnesses should be seen as an 
adaptive mechanism, such as in starvation, or rather as a maladaptive mechanism. On one hand, it 
seems logical to assume that a reduction in serum T3 would decrease TH action in important T3 
target organs such as liver and muscle, thereby affecting metabolism which might be beneficial in 
critically ill patients. On the other hand, one might argue that patients with prolonged critical illness  
show clear symptoms and signs that resemble those observed in hypothyroidism, including impaired 
consciousness and myocardial function, hypothermia, neuropathy and muscle weakness, as well as 
atrophy of the skin and hair loss, which together might impede  recovery. 13,14 Although the 
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hypothesis that NTIS in ICU patients  could be maladaptive has been discussed extensively 9 
surprisingly few clinical studies (in part RCTs) aimed at modulating NTIS in order to improve clinical 
outcome have been published. When considering clinical intervention studies, irrespective of their 
design, the risk-benefit ratio may seem favorable with a majority showing benefit and only a minority 
showing harm, but this ratio cannot really be assessed when considering only RCTs with clinically 
relevant outcome measures such as mortality or morbidity (see Table 1).   
 
Pathogenesis of NTIS  
 
A) Altered HPT axis feedback regulation and local TH metabolism  
Severe illness induces profound alterations in thyroid hormone economy resulting in a down-
regulation of the HPT axis both at the hypothalamic and pituitary level in association with a decrease 
in circulating TH concentrations. 3 This observation points to marked alterations in negative feedback 
regulation in the HPT axis during NTIS. 2 The central down regulation of the HPT-axis during NTIS in 
humans was confirmed by the observation in autopsy samples of decreased TRH gene expression in 
the hypothalamic paraventricular nucleus (PVN) of patients with NTIS. The observed TRH mRNA 
expression in the PVN showed a positive correlation with pre-mortem plasma TSH and T3. 15 In 
addition, simultaneous changes in liver thyroid hormone metabolism contribute to the characteristic 
changes in plasma thyroid hormones levels: low plasma T3 and high plasma rT3, normal or low-
normal plasma TSH, and -during severe illness- low plasma T4. 3 
Although the mechanisms involved in these seemingly paradoxical HPT axis changes are only 
incompletely understood, animal studies using a variety of NTIS models have elucidated some 
aspects of the pathogenesis of NTIS. NTIS induces specific alterations in enzymes involved in TH 
metabolism (deiodinases type 1, 2 and 3 or D1, D2 and D3), TH transporters and TH receptors (TRα 
and TRβ). 3 For example, the induction of acute inflammation in rodents by a single peripheral 
injection of bacterial endotoxin or lipopolysaccharide (LPS) stimulates D2 mRNA expression in 
tanycytes lining the third ventricle in the hypothalamus. 16,17 Conceivable, this D2 upregulation is 
followed by an increased local production of T3, which subsequently lowers TRH mRNA expression in 
the PVN as observed in humans  (see figure 1). 15,18,19 Although an increase in D2 activity has not been 
proven yet, experiments in an in vitro co-culture system confirmed that glial D2 modulates T3 
concentrations and gene expression in neighboring neurons. 20 Thus, inflammation inhibits 
hypophysiotropic TRH neurons probably via increased D2 activity thereby explaining the 
hypothalamic down regulation of the HPT axis during NTIS.  
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In the periphery, the liver is one of the key TH metabolising organs. It expresses the TH transporters 
monocarboxylate transporter 8 (MCT8) and monocarboxylate transporter 10 (MCT10), both D1 and 
D3 (although D3 is expressed at very low levels in a healthy liver) and the TRβ1 as well as TRα1 [a 
more detailed overview of cellular thyroid hormone metabolism is given in figure 2]. Although liver 
D1 contributes only for approximately 20% of the circulating T3 in humans, 21 its involvement in the 
pathogenesis of the NTIS has been extensively studied. 22 Human studies showed reduced liver D1 
mRNA expression and enzyme activity during illness, suggesting a role for liver D1 in the 
pathogenesis of illness induced changes in plasma T3 and rT3. 22  
Critical illnesses that include a significant hypoxia/ischemia component exhibit a significant increase 
in TH catabolism via induction of D3. This has been shown originally in post-mortem tissues of ICU 
patients 23 and later in a series of animal models including myocardial 24 and brain infarction. 20 Thus, 
it is likely that induction of D3 during NTIS in tissues that normally express no, or only very little D3 
contributes significantly to the abnormalities in thyroid economy observed during ischemic injury. 25       
 
B) NTIS is part of the acute phase response 
Several clinical studies performed more than 20 years ago showed a clear relationship between the 
changes in thyroid hormone metabolism and the activation of a variety of pro-inflammatory 
cytokines. 26,27 Cytokines are important mediators of the acute phase response affecting fever, 
leucocytosis, the release of stress hormones and the production of acute phase proteins. Cytokines 
are also able to affect the expression of many proteins involved in thyroid hormone metabolism and 
are causally involved in the pathogenesis of NTIS. 28 LPS stimulation of a variety of cells results in a 
strong inflammatory response characterized by the production of a variety of cytokines including 
Tumor Necrosis Factor α (TNFα), Interleukin-1 (IL-1), and Interleukin-6 (IL-6). For the induction of 
cytokines the activation of inflammatory signaling pathways is mandatory, including nuclear factor 
kappa-light-chain-enhancer of activated B cells (NFκB) and activator protein (AP)-1. 29 It was recently 
shown that activation of NFκB plays an important role in the upregulation of D2 in hypothalamic 
tanycytes during inflammation. 30, 31 D1 is also sensitive to cytokines; D1 expression in a liver cell line 
decreases upon IL-1β stimulation and this response can be abolished by simultaneous inhibition of 
NFκB and AP-1.32 Summarized, cytokines, activated as a result of the inflammatory response, are 
causally involved in the pathogenesis of NTIS, making NTIS part of the acute phase response.  
 
C) Differential effects of illness on thyroid hormone action in metabolic organs 
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Energy homeostasis changes dramatically during illness, since activating the immune system involves 
energy expenditure at the same time when food intake is decreased. Although the common view is 
that NTIS results in overall down-regulation of metabolism in the organism in order to save energy, 
recent work has shown great variability between various key metabolic organs and tissues in the 
expression of genes encoding proteins involved in thyroid hormone (TH). 3 Interestingly, these tissues 
included cells that until recently were not known to be TH responsive such as granulocytes, 33 
macrophages 34 and lung epithelial cells (see figure 4). 35 
Thyroid hormones are important for skeletal muscle function as a variety of genes expressed in 
muscle are regulated by T3. TH signalling was shown to be altered in skeletal muscle tissue during 
illness depending on the type (acute inflammation or bacterial sepsis) and stage (acute or prolonged) 
of illness. 36-38 It is unknown at this stage whether the differential alterations in muscle thyroid 
hormone metabolism during illness are clinically relevant, although muscle dysfunction has been 
associated with changes in muscle thyroid hormone metabolism during prolonged critical illness. 39-42  
Recently it has become clear that TH target cells/organs respond to inflammation by increasing D2 or 
D3 expression, thereby affecting cellular function. For example, stimulation of macrophages with 
bacterial endotoxin increases D2 expression, which was shown to be essential for cytokine 
production and phagocytosis. 34 Moreover, granulocytes show marked D3 expression when 
infiltrating an infected organ. 43 A functional role for this phenomenon was suggested by the 
observation that the lack of D3 in mice severely impairs the bacterial clearance capacity of the host. 
44 The induction of D3 in activated granulocytes not only inactivates thyroid hormone but also yields 
substantial amounts of iodide which may be used by the cell for bactericidal and tissue-toxic systems. 
45 Summarized, the presence of D3 in activated granulocytes suggests a novel (and protective) role 
for the deiodinating enzymes in the defense against acute bacterial infection. 
 
D) The role of nutrition (see figure 3) 
Critical illness is associated with loss of appetite and poor oral and enteral nutritional intake. 46 As 
fasting in healthy subjects induces a similar NTIS response as observed in critically ill patients, 12 
decreased caloric intake during illness might contribute to the development of NTIS in a major way. 
The mechanism by which fasting induces a decrease in serum TH is multifactorial and includes a 
decrease in serum leptin, and downregulation of hypothalamic hypophysiotropic TRH neurons 
contributing to persistently low serum TSH. 47 At the organ level, there is decreased activity of the 
deiodinase type-1 (D1), the enzyme driving the conversion of T4 into the biologically active T3 and 
clearing the biologically inactive reverse T3 (rT3). Increased activity of type-3 deiodinase (D3), the T3 
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inactivating enzyme, has also been reported. 48 Three clinical studies comparing patients under 
different nutritional strategies indeed indicated that decreased caloric intake during critical illness is 
associated with a more pronounced NTIS. 49-51  
Recently, the large randomized controlled EPaNIC trial compared two nutritional regimens in 4640 
adult ICU patients at risk of malnutrition: the “early parenteral nutrition (PN) group” received 
parenteral nutrition within 48h of ICU admission to supplement insufficient enteral nutrition, 
whereas the ”late PN group” did not start with parenteral nutrition to supplement enteral nutrition 
before day 8. 52 This study demonstrated that tolerating a nutritional deficit during the first week of 
critical illness as compared to the early administration of supplemental parenteral nutrition, resulted 
in fewer complications and accelerated recovery. 52 Tolerating a fasting response thus appears to be 
beneficial for the patient. Of interest, a subanalysis of the EPaNIC trial (n=280) demonstrated that 
late feeding reduced complications and accelerated recovery of patients with NTIS, but aggravated 
the changes in circulating levels of plasma TSH, total T4, T3, and the T3 to rT3 ratio. The opposite was 
observed with early feeding. 53  
Thus, the peripheral metabolism of T3 is affected by decreased nutritional intake during acute critical 
illness. A subanalysis of the EPaNIC trial indicated that the inactivation of T3 to rT3, as part of the 
fasting response, might be a beneficial adaptation during acute illness. 53 Targeting  fasting blood 
glucose levels with intensive insulin therapy in children with critical illness to 2.8–4.4 mmol/L in 
infants and 3.9–5.6 mmol/L in children, thereby mimicking a fasting response, resulted in improved 
outcome 54  while aggravating  the peripheral NTIS at the same time. Multivariate Cox proportional 
hazard analysis indicated that the further reduction of T3/rT3 explained part of the therapy benefit 
on mortality. 55 
Together, these findings suggest that thyroid economy is affected by decreased nutritional intake 
during acute critical illness, and the inactivation of T4 to rT3 and T3 to T2, as part of the fasting 
response, might be a beneficial adaptation during acute illness. 53 In particular, the acute peripheral 
inactivation of TH by inner ring deiodination during critical illness is likely a beneficial adaptation. 
Indeed, the reduced amount of circulating active T3 could be interpreted as an attempt of the body 
to decrease the metabolic rate and reduce expenditure of scarce energy, to prevent protein 
breakdown and, thereby, to promote survival. In contrast, the central lowering of T4 could be 
deleterious.  Consistent with this interpretation is the observation that especially the more severely 
ill patients display a decline in circulating T4 levels, whereas virtually all ill patients display low T3 and 
high rT3 levels already from admission to the ICU. 36  
 
Diagnosis and management of severe primary thyroid disorders in ICU patients  
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The high prevalence of NTIS in ICU patients and the magnitude of HPT axis changes in these patients 
can make it difficult to distinguish NTIS from untreated primary hypothyroidism. Levothyroxine 
treatment should be continued during the ICU stay in patients previously known to have 
hypothyroidism. Although this practice seems trivial, prescription and continuation of chronic 
therapy is not always a primary focus of care in the ICU setting. A retrospective chart review study in 
a tertiary referral ICU showed that thyroid replacement therapy was not prescribed for more than 7 
days in 17.3% of patients and omitted entirely in 3/133 patients. 56 The diagnosis of primary 
hypothyroidism in severely ill patients who were unknown to have hypothyroidism before admission 
can be difficult as serum TH, especially T3, is decreased in most ICU patients due to NTIS. In patients 
clinically suspected to have severe hypothyroidism, the most useful test is plasma TSH, as a normal 
plasma TSH virtually excludes primary hypothyroidism. In patients with a combination of primary 
hypothyroidism and NTIS, serum TSH is still high and responsive to levothyroxine treatment. 
However, it should be kept in mind that, in hypothyroid patients, the high serum TSH concentration 
may decrease during the acute phase of illness especially if dopamine or high doses of 
glucocorticoids were given. Thus, high serum TSH in combination with low serum T4 is indicative of 
hypothyroidism, although this combination can also be found in patients recovering from NTIS.  A 
high serum T3/T4 ratio and a low serum rT3 favor the presence of hypothyroidism, as the ratios are 
opposite in NTIS, but the diagnostic accuracy of these measurements is limited. 4 Especially in 
patients with long-standing and untreated hypothyroidism, cold exposure, infection and vascular 
accidents may trigger the development of myxedema coma. This is a life-threatening condition with a 
high mortality of ~50%. 57 Key clinical features are hypothermia and altered consciousness, and 
laboratory findings include elevated TSH with low or undetectable T4 and T3. Of note, the presence 
of NTIS may reduce the degree of TSH elevation. Active management is important and depends on 
the recognition of the clinical features.  The treatment of myxedema coma aims at TH replacement, 
treatment of the underlying condition and supportive care. In addition, stress dose glucocorticoids 
should be given (e.g., 100 mg hydrocortisone every 8h) as concomitant autoimmune primary adrenal 
insufficiency may be present, especially in patients with hypoglycemia. 58  
A low serum TSH may point to thyrotoxicosis, especially if serum FT4 is high as well. The degree of 
TSH suppression correlates with the likelihood of thyrotoxicosis. The combination of suppressed TSH, 
high FT4 and normal T3 may point to the combination of thyrotoxicosis and NTIS, and has been 
referred to as T4-thyrotoxicosis. 4 Needless to say, physical examination (goiter, proptosis) and the 
presence of thyroid antibodies (anti TPO, TBII) may give further information regarding the probability 
of thyrotoxicosis.  In the ICU setting some patients may present with decompensated thyrotoxicosis, 
or thyroid storm, which is a life-threatening condition. Importantly, TH levels do not distinguish 
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patients with thyroid storm from those with severe thyrotoxicosis as thyroid storm is a clinical 
diagnosis. The classical findings include fever, (supraventricular) tachycardia, gastrointestinal 
symptoms, and altered mental state including confusion, delirium or even coma. 57 Precipitating 
factors include surgery, parturition, and infection. Therapy of thyroid storm generally requires ICU 
monitoring and aims at restoring thyroid gland function while diminishing TH effects on peripheral 
tissues using, a combination of beta-blockers, thyrostatics, i.v. glucocorticoids and eventually high-
dose of iodide compounds. 59 In a recent retrospective cohort study in acutely hospitalized thyrotoxic 
patients, the presence of CNS dysfunction was the only significantly different clinical feature between 
patients with thyroid storm and patients with compensated thyrotoxicosis. Thus, thyrotoxic patients 
with possible thyroid storm and altered mentation should be treated aggressively with supportive 
measures and antithyroid drugs. 60  
 
Treatment/management of NTIS  
 The question whether interventions aimed at normalizing thyroid hormone levels in prolonged 
critically ill patients are beneficial has not been satisfactorily answered to date. Clinical studies 
reporting interventions in NTIS patients are listed in Table 1. There are only few, rather small RTCs 
assessing the effects of treatment with thyroid hormone in patients with NTIS. These trials report 
results obtained in a large variety of patient groups, e.g. patients with acute renal failure, 61 burn 
injury, 62 cardiac surgery, 63 - 66 and ICU patients with low T4 levels. 67 Furthermore, the age of the 
study population in these studies varies considerably, ranging from premature newborns to children 
and adults. Disease severity is another variable, ranging from critical illness at the medical ICU to 
heart surgery in relatively healthy subjects. Surprisingly little consistency is present in the choice of 
the active study drug, as both T3 (orally as well as iv) and levothyroxine (LT4) have been used. In the 
context of studies with T4 or T3, it should be kept in mind that normalizing TH levels in serum does 
not necessarily result in normal tissue concentrations of TH. This was clear from one study in patients 
with critical illness who received thyroid hormone treatment. 22 In these patients, the increase in liver 
T3 concentrations after thyroid hormone treatment was disproportionally high compared to the 
increase in serum and muscle T3 concentrations. In addition to treatment with TH, the effect of 
selenium (Se) on NTIS per se and on clinical outcome parameters has been studied. 68, 69 Recently, the 
effect of N-acetyl-cysteine (NAC), an antioxidant that restores intracellular glutathione (a co-factor 
required for D1 catalytic activity), on NTIS was studied in a small RCT. NAC administration appeared 
to prevent the derangement in thyroid hormone concentrations commonly occurring in the acute 
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phase of acute myocardial infarction, indicating that oxidative stress is involved in the pathogenesis 
of NTIS in acute MI. 70   
An unresolved and somewhat controversial issue is the question if there is a place for thyroid 
hormone treatment in patients with heart failure. Although the failing heart shows molecular 
changes partly overlapping with the hypothyroid heart, this does not necessarily imply that 
treatment of patients with heart failure and low serum T3 in the setting of NTIS is favorable. 8 The 
therapeutic use of TH in patients with heart failure has not been adequately studied, although some 
encouraging trials have been reported. One small RCT in patients with dilated cardiomyopathy 
showed beneficial effects of medium-term (3 months) levothyroxine treatment on cardiac 
performance, 71 while another RCT showed that the thyroid hormone analog 3,5 
diiodothyropropionic acid (DITPA) improved some hemodynamic parameters albeit without evidence 
for symptomatic benefit in heart failure. 72 
Finally, hypothalamic neuropeptides including (combinations of ) Growth Hormone Releasing 
Hormone (GHRH), Growth Hormone Releasing Peptide (GHRP)-2, Gonadotropin Releasing Hormone 
(GnRH) and TRH have been used in prolonged critically ill patients in an attempt to stimulate the 
anterior pituitary gland, thereby restoring endocrine function in terms of plasma concentrations and 
hormone pulsatility. 10,73-76 Overall, the RCTs in critical illness using T3 and/or T4 have been largely 
negative in terms of clinical benefit. An overview of studies including their clinical endpoints is 
presented in Table 1.  It should be noted, however, that hypothalamic neuropeptides, notably TRH in 
combination with GHRP-2 iv, can restore circulating thyroid hormone concentrations as well as TSH 
pulsatility to a remarkable extent. In addition, this strategy improved overall metabolism, including 
bone markers and anabolic parameters. The interpretation of these findings as reflecting insufficient 
hypothalamic drive of pituitary TSH release in protracted critical illness was supported by a study in 
deceased patients with NTIS who appeared to have decreased hypothalamic TRH mRNA expression 
in the PVN, in correlation with decreased pre-mortem plasma TSH and T3 concentrations. 15 
However, the studies performed with hypothalamic neuropeptides comprised only small patient 
numbers while at present it is unclear if treatment with those neuropeptides offers clinical benefit in 
terms of morbidity and mortality. In sum, no definitive conclusion about the efficacy of thyroid 
hormone treatment in ICU patients with NTIS can be drawn at this stage. 8  
It should be noted that aside from possible benefit, there may even be possible harm. In particular, 
the study by Acker et al in patients with acute renal failure raised some concern because of  a 
tendency towards increased mortality after treatment with levothyroxine (see Table 1) without any 
beneficial effect on outcome, e.g. in terms of dialysis need. 61 However, the observed mortality in the 
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control group in this study was less than expected, which does not necessarily justify the 
interpretation that the intervention was harmful. It is evident that none of the reported studies were 
adequately powered to detect clinically meaningful differences. Finally, the majority of these trials 
used rather high doses of either T4 or T3, probably inducing further suppression of pituitary TSH 
release and altered tissue deiodinase activities. The use of neuropeptides, including TRH, to stimulate 
the HPT axis in a more physiological way, may be promising in this respect. Large RCTs in well-defined 
patient groups will be required to investigate possible positive effects of this approach in terms of 
outcome. High priority should be given to RCTs comparing the effect of the hypothalamic 
neuropeptides including TRH with placebo, as this approach has already been shown to partially 
normalize serum TH parameters while at the same time improving metabolic markers. 10 However, 
these effects have been shown only in small studies that were not powered to study clinically 
relevant outcome measures such as mortality or morbidity. Another interesting possibility will be to 
investigate treatment with recombinant human (rh)TSH, as this is –similar to THR- a physiological 
stimulus for TH release from the thyroid.  A pilot study presented at the 2013 Annual Meeting of the 
European Thyroid Association showed that daily low dose (30 µg) TSH treatment in patients with 
central hypothyroidism was sufficient to cause increases of plasma TSH levels to the normal range. 
The treatment also improved quality of life and sleep behaviour (abstract P153, Dixit et al Eur Thyroid 
J 2013: 2(suppl 1)). It will be of interest to investigate if this approach can be used in ICU patients 
with NTIS to normalize TSH and TH, and -if so - to improve clinical outcome. Again, this should be 
done in adequately powered, randomized and placebo-controlled studies. 
 
Conclusion 
In the classic view, NTIS is a syndrome occurring during a variety of illnesses marked by decreased 
plasma TH concentrations with unclear consequences. Recent studies have shown that the 
alterations in thyroid economy during NTIS reflects profound and complex changes at the level of the 
HPT axis, in terms of setpoint regulation, and at the organ level in terms of local TH metabolism 
(figure 5). Whether the observed changes in critically ill patients are beneficial or deleterious in terms 
of outcome probably depends on disease stage and severity, the need of prolonged vital support, 
and environmental factors including parenteral nutrition. At present, there is no evidence-based 
consensus or guideline advocating thyroid hormone treatment of NTIS in the critically ill patients. 
Adequately powered RCTs should be performed to define whether active management of NTIS, e.g. 
using hypothalamic neuropeptides including TRH, may yield clinical benefit in terms of outcome. 
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Method  
We searched MEDLINE (via Ovid, 1946 to March 2014), Embase (via Ovid, 1947 to March 2014) and 
the Cochrane Central Register of Controlled Trials (The Cochrane Library, 6 March 2014). The search 
strategy consisted of subject headings and free-text words related to the concepts "critically ill 
patients" or "intensive care" or "sepsis" in combination with "thyroid dysfunction" or "euthyroid sick 
syndrome" or "thyroid hormones". The search strategy was limited to English language publications. 
No publication date restrictions were applied. References that were used were selected based on 
title.  
 
Contributors: EF and AB wrote and revised the manuscript, LL wrote the manuscript and ACB revised 
the manuscript.  
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Table 1: A selected overview of clinical studies reporting interventions in NTIS patients (A: children, B: adults). 
Y: yes and N: no, when Y is indicated in the column “beneficial/positive” the effect of treatment (defined by the 
authors) is positive.  When Y is indicated in the column “harmful”, harmful effects (defined by the authors) 
have been reported. GA, gestation; iv, intravenous; CNS, central nervous system; GH, growth hormone; PRL, 
prolactin; se, selenium. 
 
Setting RCT 
 Y/N 
Intervention 
(duration) 
Main Outcome 
parameters 
Beneficial/ 
positive 
(endpoints)  
Harmful 
 
Reference 
A       
Children after 
cardiopulmonary 
bypass surgery, 
range 2 days – 
10.4 years (n=40) 
Y 
T3, 2µg/kg iv at day 
1 after surgery and 
1 µg/kg for 12 days 
Cardiac function,  
ICU measures 
Y N 
77
 
Premature 
newborns less 
than 37 GA 
(n=100) 
N 
LT4 (25 µg/day) plus 
T3 (5 µg/day) oral 
(once) 
Mortality Y N 
78
 
Premature 
newborns less 
than 32 weeks of 
GA (n=49) 
Y 
LT4, 10 (iv) or 20 
µ/kg (through 
nasogastric tube) 
for 21 days 
Chronic lung 
disease, death, CNS 
damage, sepsis 
N N 
79
 
 
Children < 18 yrs 
with cessation of 
neurologic 
function during 
evaluation for 
organ recovery 
(n=171) 
N 
Weight based LT4 
bolus followed by 
infusion 
Vasopressor score Y N 
80
 
B       
Protracted critical 
illness (n=14) 
Y 
TRH (1 µg/kg/h) iv 
plus GHRP-2 (1 
µg/kg/h) iv for 5 
days 
GH and TSH 
secretion; 
biochemical 
anabolism/cataboli
sm parameters 
Y N 
10
 
Critical illness 
(n=76) 
Y 
GHRP-2, alone or in 
combination with 
TRH and GHRH 
(each peptide 1 
µg/kg/h) 
Synchrony among 
GH, TSH and PRL 
release 
Y N 
73
 
Critical illness 
(n=40) 
Y 
Combinations of 
GHRH, GHRP-2 
(both 1 µg/kg), TRH 
(200 µg) given as 
bolus, time interval 
6h 
Serum GH, TSH, T3 
and T4 
concentrations 
Y N 
74
 
Protracted critical 
illness (n=20) 
Y 
Combinations of 
GHRH, GHRP-2, TRH 
start with bolus 1 
µg/kg followed by 1 
µg/kg/h (two 
consecutive nights) 
Serum hormone 
concentrations 
Y N 
75
 
Protracted critical 
illness (n=33) 
Y 
Combinations of 
GHRH, GHRP-2, TRH 
(each 1 µg/kg/h), 
GnRH (0,1µg/kg/90 
min) for 5 days 
Serum hormone 
and metabolic 
marker 
concentrations 
Y N 
76
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Elective coronary 
bypass surgery 
(n=80) 
Y 
T3 (125 µg/day) 
orally (7 days pre-
op until discharge) 
Hemodynamic 
data, morbidity and 
mortality 
Y 
(hemodynami
c parameters) 
N (morbidity, 
mortality) 
N 
63
 
Burn injury 
(n=36) 
Y 
T3 (200 µg/day 
orally or nasogastric 
tube in 4 divided 
doses until wounds 
were healed 
Mortality, resting 
metabolic rate 
N N 
62
 
Coronary bypass 
surgery (n=60) 
Y 
T3 (0,8µg/kg) iv for 
6 h 
Operative 
outcome, 
morbidity, 
mortality 
N N 
64
 
Coronary bypass 
surgery (n=100) 
Y 
T3 (20 µg/12h) oral 
(48 h) 
Serum T3, 
hemodynamic 
variables, 
morbidity 
N N 
65
 
High risk valvular 
heart surgery 
(n=50) 
Y 
T3 (20 µg/12h) oral 
(24 h) 
Vasopressor need Y N 
66
 
Medical ICU 
patients with low 
T4 (n=23) 
Y 
1,5 µg/kg BW LT4 iv 
(2 weeks) 
Mortality N N 
67
 
Acute renal 
failure (n=59) 
y 
LT4 infusion, 150 
µg/20 ml every 12h 
for 48h 
% dialysis, % 
recovery,  mortality 
N 
Y? 
(increased 
mortality) 
61
 
Idiopathic dilated 
cardiomyopathie 
(n=20) 
Y 
100 µg LT4/day for 
3 months 
Cardiac 
performance 
Y N 
71
 
       
Congestive heart 
failure (n=86) 
Y 
Thyroid hormone 
analogue DIPTA, 
2/day, max dose 
360 mg/day 
Composite 
congestive heart 
failure endpoints 
N 
Y 
  
72
 
       
NTIS after major 
trauma (n=31) 
Y 
Se (500 µg/day) 
with or without 
vitamin E and zinc 
supplement vs 
placebo (5 days) 
Serum Se levels, T4 
levels, duration of 
mechanical 
ventilation 
Y (T4 and Se 
plasma levels) 
+/- 
(ventilation) 
N 
68
 
Septic ICU 
patients (n=40) 
Y 
High dose Se (158  
µg/day, 3 days), 
followed by 
standard dose Se-
selenite (31,6 
µg/day) 
Serum Se 
concentrations, 
oxidative damage 
parameters, need 
for renal 
replacement  
therapy 
N N 
79
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Legends 
Figure 1: Schematic model of hypothalamic thyroid hormone signalling during inflammation. Inflammation 
activates the NfκB pathway in tanycytes, specialised cells lining the third ventricle (III). Tanycytes express D2, 
the main T3 producing enzyme in the brain, the promoter of which contains NfκB responsive elements. Binding 
of NfκB increases D2 expression and activity, and  this stimulates the conversion of the prohormone T4 into T3. 
T3 will enter adjacent neurons and bind to neuronal TRs thereby regulating transcriptional activity of TRH.  
Figure 2: Schematic model of cellular thyroid hormone metabolism. Cellular entry of TH is necessary for 
intracellular conversion and for exerting an effect via binding to the nuclear TR. Two categories of thyroid 
hormone transporters have been described, i.e., the organic anion transporters and the amino acid 
transporters. 
1,
 
81-83
 Once transported into the cell, thyroid hormones can be metabolized by outer or inner ring 
deiodination through the iodothyronine deiodinases. These enzymes belong to a selenocysteine containing 
enzyme family and comprise three types; type 1 (D1), 2 (D2) and type 3 (D3). 
84
 D1 is able to deiodinate  the 
inner- and outer-ring of T4 as well as  the outer ring of rT3. D1 is expressed in liver, kidney, thyroid and pituitary 
and localized in the plasma membrane.
85, 86
 D2 is localized in the endoplasmic reticulum and deiodinates T4 
into the biologically active T3. D2 is the main enzyme involved in the production of tissue T3 and therefore 
heavily involved in local thyroid hormone metabolism. 
87, 88
 D3 is localized in the plasma membrane and can be 
viewed as the major thyroid hormone inactivating enzyme, as it catalyses inner-ring deiodination of both T4 
and T3, exclusively resulting in the production of biologically inactive rT3 and rT2. 
21
 The balance between D2 
and D3 determines the availability of cellular T3 which enters the nucleus and binds to the nuclear receptor 
complex. Binding of T3 to the TR complex regulates transcriptional activity of T3-target genes.   
Figure 3: Schematic representation of the effect of parental nutrition during NTIS.  Critical illness-induced 
NTIS is characterized by low circulating T3 and elevation of rT3 levels. Low hypothalamic TRH mRNA expression, 
low circulating TSH and low T4 are also observed. When early full parenteral support is administered to resolve 
the caloric deficit, the peripheral changes in the thyroid axis partly normalize, but not its central suppression. 
89
 
Figure 4: Schematic and simplified overview of a variety of observed differential effects of NTIS on deiodinase 
activities within various tissues probably inducing inter-organ differences in T3 bioavailability in the presence of 
similarly decreased plasma T3. 
Figure 5: Schematic representation of the variety of changes occurring during critical illness. Solid lines 
represent a causal relation, while a dashed line represents a probable effect. The scheme is based on both 
experimental and human studies. The net result of altered tissue TH metabolism may be beneficial or 
maladaptive, dependent on disease duration and severity.  
17 
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